This is a numbers-first look at Piramal Enterprises (PEL), covering income trends, margins, valuation, and shareholding.
Piramal Enterprises Revenue Trend
Revenue rose 4.3% to ₹10,612 Cr in FY2025 for Piramal Enterprises, against ₹10,178 Cr the year before.
On a 10-year view, revenue grew at 7.6% per year from ₹5,123 Cr to ₹10,612 Cr. Respectable, though not in the high-growth bracket.
Piramal Enterprises's ₹10,612 Cr revenue base puts it in the major bracket among pharmaceuticals companies in India.
Looking at the year-on-year numbers, Piramal Enterprises has seen 3 years of unbroken revenue growth.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹10,612 Cr | +4.3% |
| FY2024 | ₹10,178 Cr | +12.0% |
| FY2023 | ₹9,087 Cr | +14.9% |
| FY2022 | ₹7,911 Cr | -39.9% |
| FY2021 | ₹13,173 Cr | — |
View Piramal Enterprises's full 10-year revenue trend with CAGR analysis →
Piramal Enterprises Profitability
On a per-share basis, diluted earnings were ₹21.33 in FY2025 versus ₹-72.82 in FY2024.
Is Piramal Enterprises Undervalued
Based on the P/E Ratio model, Piramal Enterprises's fair value works out to ₹545 — 51.5% downside from where it trades today.
Piramal Enterprises shares are currently trading at ₹1,124.20.
Craytheon also calculates intrinsic value using the EPS Growth model. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹545 | 51.5% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
See all valuation models for Piramal Enterprises with detailed assumptions →
Piramal Enterprises Shareholding Pattern
A stable promoter holding of 46.2% over 4 quarters suggests the management group is comfortable with its position.
Foreign institutions moved their stake up to 15.2% from 14.9% over the past year.
DII holding is at 15.2%, up from 14.9% in the year-ago quarter.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2025 | 46.2% | 15.2% | 15.2% | 22.8% |
| Mar 2025 | 46.4% | 16.1% | 14.3% | 22.8% |
| Dec 2024 | 46.3% | 16.4% | 13.8% | 23.1% |
| Sep 2024 | 46.3% | 14.9% | 14.9% | 23.4% |
Track quarterly shareholding changes for Piramal Enterprises →
Piramal Enterprises Balance Sheet
Proportional view as of 22 Sep 2025. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹949.43B, up 14.9% YoY from ₹826.05B.
Other Assets accounts for 76.9% of the total, ahead of Cash & ST Investments (19.8%) and Property, Plant & Equipment (2.9%).
Capital structure: 28.5% equity, 69.0% debt, 2.5% operating liabilities. Over the year, debt is up 22.2% and equity is up 2.0%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 188.15B |
| Receivables | 494.70M |
| Property, Plant & Equipment | 27.65B |
| Intangibles & Goodwill | 2.58B |
| Other Assets | 730.56B |
| Category | Value |
|---|---|
| Equity | 270.96B |
| Short-term Debt | 654.88B |
| Trade Payables | 5.04B |
| Other Liabilities | 18.56B |
Piramal Enterprises Key Takeaways
To sum up Piramal Enterprises's financial position: the data paints a clear picture for investors evaluating this pharmaceuticals stock.
Revenue of ₹10,612 Cr in FY2025, up 4.3% year-over-year.
Long-term revenue has been compounding at 7.6% annually over 10 years.
The company is profitable, with a net margin of 4.6% and net income of ₹485 Cr.
The P/E Ratio model implies 51.5% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Craytheon's full analysis of Piramal Enterprises goes deeper: three valuation models, growth metrics, and 10 years of financial data.